Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases
Version of Record online: 5 APR 2012
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 12, pages 2315–2333, December 2012
How to Cite
Clark, P. M., Dawany, N., Dampier, W., Byers, S. W., Pestell, R. G. and Tozeren, A. (2012), Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases. Inflamm Bowel Dis, 18: 2315–2333. doi: 10.1002/ibd.22958
- Issue online: 15 NOV 2012
- Version of Record online: 5 APR 2012
- Manuscript Accepted: 27 FEB 2012
- Manuscript Received: 9 FEB 2012
Additional Supporting Information may be found in the online version of this article.
|IBD_22958_sm_SuppFile1.txt||23K||Supporting Information File 1: The top 200 significant genes identified for both UC/HC and CD/HC comparisons. The columns in the table show gene symbols, fold changes, and SAM p-value.|
|IBD_22958_sm_SuppFile2.txt||2K||Supporting Information File 2: Differentially expressed genes targeted by a bioactive small molecule for UC/HC and CD/HC comparisons. The columns 1, 2, and 3 indicate the gene symbol, fold change in UC and fold change in CD, respectively.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.